Cartesian Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Cartesian Therapeutics, Inc. (RNAC) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$19.68 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2017-03-28
- Cartesian Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-12-31 was $1.56M.
- Cartesian Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-09-30 was -$5.47M.
- Cartesian Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2015-12-31 was -$7.64M.
- Cartesian Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2015-09-30 was -$5.61M.
- Cartesian Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$19.68M.
- Cartesian Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$22.46M.
- Cartesian Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was -$12.69M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2016-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-28 | -$3.91M derived: sum of 2 quarters · filed 2017-03-28 | -$19.68M 10-K · filed 2017-03-28 | |
| 2016-09-30 | -$5.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$21.24M 10-Q · filed 2016-11-10 | ||
| 2016-06-30 | -$15.77M 10-Q · filed 2016-08-09 | |||
| 2015-12-31 | -$7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-28 | -$13.25M derived: sum of 2 quarters · filed 2017-03-28 | -$22.46M 10-K · filed 2017-03-28 | |
| 2015-09-30 | -$5.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$14.82M 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | -$9.21M 10-Q · filed 2016-08-09 | |||
| 2014-12-31 | -$12.69M 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |